News
Esketamine monotherapy is linked to greater 28-day symptom reduction in treatment-resistant depression vs placebo, new research shows.
From sarcopenia to ALS, researchers are exploring creatine’s broader clinical potential — but more trials are needed to confirm its value.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results